B7-H4 Antibody Formulations for Stable Long-Term Storage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for stable pharmaceutical compositions comprising B7-H4 antibodies for effective cancer treatment, as existing formulations face stability issues under long-term storage and handling conditions.
Innovation Solution
The development of pharmaceutical compositions comprising B7-H4 antibodies with specific CDR sequences, buffered at pH 4.5 to 6, including acetate or citrate, with excipients like sucrose and surfactants like polysorbate 20, to maintain stability and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If B7-H4 antibody formulations are stored under long-term conditions, then the antibody may degrade or form variants, but maintaining stability requires specific formulation conditions that increase complexity
Solution Approach 1:
The patent optimizes specific formulation parameters including pH (4.5-6.0), buffer type (acetate or citrate), sugar concentration (20-40% w/v), and surfactant concentration (0.01-0.1% w/v) to achieve stable antibody storage without excessive complexity
Solution Approach 2:
The patent uses buffer systems (acetate or citrate) as intermediaries to maintain pH stability, and sugars (sucrose, trehalose, sorbitol) as protective intermediaries that prevent antibody aggregation and degradation during long-term storage
2Reliability
If the formulation uses acidic pH to stabilize the antibody, then binding affinity is maintained, but acidic conditions may promote formation of acidic variants
Solution Approach 1:
The patent identifies an optimal pH range (4.5-6.0) that balances binding affinity maintenance with minimization of acidic variant formation, and uses buffer systems to maintain this pH range during storage
Solution Approach 2:
The formulation combines multiple components (antibody, buffer, sugar, surfactant) in specific ratios to create a composite system where the sugar and surfactant protect the antibody from degradation while the buffer maintains optimal pH
Data Source
AI summary
The present disclosure provides pharmaceutical compositions comprising antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4). The present disclosure also prides methods for treating disorders, such as cancer, by administering such pharmaceutical compositions.